Search
Selected Filter
Displaying 11–20 of 275 research results
-
Eye On the Cure Research News
The newly approved drug reduces the pathologic hunger associated with BBS
-
Over Thirty Presentations Highlighted during the 2022 Retinal Cell & Gene Therapy Innovation Summit
Eye On the Cure Research NewsIn its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.
-
Luxa Doses First Participant in Clinical Trial of RPE Stem Cells for Dry AMD Patients
Eye On the Cure Research NewsThe company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
-
ProQR’s Sepofarsen Improves Vision Significantly for Girl with LCA10
Eye On the Cure Research NewsHowever, the Phase 2/3 Illuminate trial for sepofarsen didn’t meet its endpoints at 12 months
-
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
Eye On the Cure Research NewsThe three-month results support the planned launch of the company’s Phase 2/3 Vista trial
-
Enhanced Implantable Miniature Telescope Moving into Clinical Trial for AMD Patients
Eye On the Cure Research NewsThe device is designed for people with late-stage AMD who have no treatment options
-
Gene Knock-Out, Replacement Therapy for RP-RHO Performed Well in Lab Study
Eye On the Cure Research NewsEditas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
-
Promising Results from Lab Study of Gene Therapy for Cone-Rod Dystrophy
Eye On the Cure Research NewsThe study is an important step toward a clinical trial of the approach
-
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
Eye On the Cure Research NewsThe company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
-
Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community
Science EducationThe Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
